Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6192793 | 1.00 | GRIK1 (0.50) | GRIK1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17510916 | 1.00 | GRIK1 (0.50) | GRIK1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL24252168 | 1.00 | GRIK1 (0.50) | GRIK1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3252245 | 0.88 | GRIK1 (0.51) | GRIK1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL28014450 | 0.87 | GRIK1 (0.57) | GRIK1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18022845 | 0.87 | GRIK1 (0.48) | GRIK1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29015070 | 0.84 | TRPA1 (0.51) | KMT2ACYP2D6CYP2C9CYP2C19HPGD | |
| SCHEMBL6190476 | 0.84 | KMT2A (0.48) | KMT2ACYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL16149006 | 0.84 | KMT2A (0.48) | KMT2ACYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL16156176 | 0.84 | KMT2A (0.48) | KMT2ACYP2D6CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472391-B2 | Methods and compositions using ADAM10 inhibitors to treat bacterial infections | THE UNIVERSITY OF CHICAGO (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472391-B2 | Methods and compositions using ADAM10 inhibitors to treat bacterial infections | THE UNIVERSITY OF CHICAGO (US) | 2019-11-12 | — | — | US | disclosed |
| US-20160052964-A1 | METHODS AND COMPOSITIONS USING ADAM10 INHIBITORS TO TREAT BACTERIAL INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2014165746-A1 | METHODS AND COMPOSITIONS USING ADAM10 INHIBITORS TO TREAT BACTERIAL INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165746-A1 | METHODS AND COMPOSITIONS USING ADAM10 INHIBITORS TO TREAT BACTERIAL INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| EP-1984500-A2 | ADAM10 AND ITS USES RELATED TO INFECTION | VANDERBILT UNIVERSITY (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007084488-A2 | ADAM10 AND ITS USES RELATED TO INFECTION | VANDERBILT UNIVERSITY (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1121118-A4 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LTD (GB) | 2002-09-11 | — | — | EP | disclosed |
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1121118-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2001-08-08 | — | — | EP | disclosed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000012083-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012082-A1 | FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052964-A1 | METHODS AND COMPOSITIONS USING ADAM10 INHIBITORS TO TREAT BACTERIAL INFECTIONS | ADAM10, ADAM17, ADAM9 | GRIK1 2116/4885KMT2A 3953/4885CYP2D6 4314/4885 |
| US-10472391-B2 | Methods and compositions using ADAM10 inhibitors to treat bacterial infections | ADAM10, ADAM17, ADAM9 | GRIK1 2116/4885KMT2A 3953/4885CYP2D6 4314/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | GRIK1 2530/4885KMT2A 4376/4885CYP2D6 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.